Benjamin Miriovsky, MD
Hematology & Oncology · Huntsville, ALNPI 1427234277
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,685, more than ten times the $13 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 234 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$752
- Pfizer$605
- Merck$488
- Seagen Inc.$382
- Johnson & Johnson$301
- E.r. Squibb & Sons, L.L.C.$257
- plus $2K from 34 others
Across 2 payments — averaging $2750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$6K
What the payments were for
- Speaking & faculty fees$1203%
- Food & beverage$4,47294%
- Education$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 36 | $752 |
| Pfizer | 29 | $605 |
| Merck | 23 | $488 |
| Seagen Inc. | 17 | $382 |
| Johnson & Johnson | 15 | $301 |
| E.r. Squibb & Sons, L.L.C. | 16 | $257 |
| Gilead(2 entities) | 10 | $176 |
| Bristol Myers Squibb | 6 | $145 |
| Daiichi Sankyo Inc. | 6 | $142 |
| AbbVie | 6 | $129 |
| Beone Medicines USA, Inc. | 8 | $127 |
| Boehringer Ingelheim | 4 | $102 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $94 |
| GSK | 4 | $91 |
| AVEO Pharmaceuticals, Inc. | 5 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Beigene USA, Inc. | 4 | $69 |
| Sanofi | 3 | $63 |
| Eisai Inc. | 3 | $62 |
| Array Biopharma Inc | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Bayer | 3 | $49 |
| Exelixis Inc. | 2 | $49 |
| AstraZeneca | 2 | $41 |
| Puma Biotechnology, Inc. | 2 | $34 |
| Tempus AI, Inc | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Stemline Therapeutics Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Immunocore Limited | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Genmab U.S., Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $15 |
How this compares
$4,749 in reported general payments places this provider in the 40th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 39 | $496,358 |
| IbrancePalbociclib | 28 | $341,550 |
| ErleadaApalutamide | 20 | $291,810 |
| BesremiRopeginterferon Alfa-2b-Njft | 17 | $242,821 |
| PomalystPomalidomide | 12 | $237,131 |
| SprycelDasatinib | 20 | $229,553 |
| RevlimidLenalidomide | 18 | $215,038 |
| ImbruvicaIbrutinib | 13 | $208,532 |
| ZejulaNiraparib Tosylate | 11 | $204,414 |
| VenclextaVenetoclax | 14 | $122,260 |
| EliquisApixaban | 164 | $108,946 |
| XareltoRivaroxaban | 39 | $36,658 |
| Abiraterone Acetate | 48 | $28,518 |
| LyricaPregabalin | 11 | $10,260 |
| Exemestane | 33 | $4,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $257 | $466,68432 claims |
| PfizerIbrance, Eliquis, Lyrica | $605 | $460,756203 claims |
| Johnson & JohnsonErleada, Xarelto | $301 | $328,46859 claims |
| Bristol Myers SquibbRevlimid | $145 | $215,03818 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $94 | $208,53213 claims |
| GSKZejula | $91 | $204,41411 claims |
| AbbVieVenclexta | $129 | $122,26014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Huntsville
- Ehab ElbaheshHuntsville$47K
- Ali HachemHuntsville$20K
- Daniel SchreederHuntsville$16K
- Jorge Diaz CastroHuntsville$14K
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.